Srinivas Akkaraju net worth and biography

Srinivas Akkaraju Biography and Net Worth

Director of Scholar Rock

Dr. Srinivas Akkaraju has served as a member of our board of directors since July 2022. Dr. Akkaraju is the Founder and Managing General Partner at Samsara BioCapital. Previously, from 2013 to 2016, he served as a General Partner of Sofinnova Ventures. Prior to that, he served as Managing Director of New Leaf Venture Partners. Earlier, he served as a Managing Director and Co-Founder at Panorama Capital, LLC, a private equity firm. Dr. Akkaraju was with J.P. Morgan Partners, which he joined in 2001 and of which he became a Partner in 2005. From October 1998 to April 2001, he was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group. Dr. Akkaraju received a M.D. and Ph.D. in Immunology from Stanford University. He received his undergraduate degrees in Biochemistry and Computer Science from Rice University.

What is Srinivas Akkaraju's net worth?: The estimated net worth of Srinivas Akkaraju is at least $184.33 million as of October 7th, 2024. Dr. Akkaraju owns 5,612,896 shares of Scholar Rock stock worth more than $184,327,505 as of March 29th. This net worth estimate does not reflect any other assets that Dr. Akkaraju may own. Learn More about Srinivas Akkaraju's net worth.
How do I contact Srinivas Akkaraju?: The corporate mailing address for Dr. Akkaraju and other Scholar Rock executives is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. Scholar Rock can also be reached via phone at (857) 259-3860 and via email at chu@scholarrock.com. Learn More on Srinivas Akkaraju's contact information.
Has Srinivas Akkaraju been buying or selling shares of Scholar Rock?: Srinivas Akkaraju has not been actively trading shares of Scholar Rock during the last ninety days. Most recently, Srinivas Akkaraju sold 1,175,713 shares of the business's stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.25, for a transaction totalling $34,389,605.25. Following the completion of the sale, the director now directly owns 5,612,896 shares of the company's stock, valued at $164,177,208. Learn More on Srinivas Akkaraju's trading history.
Who are Scholar Rock's active insiders?: Scholar Rock's insider roster includes Srinivas Akkaraju (Director), Jay Backstrom (President & CEO), Jeffrey Flier (Director), Junlin Ho (General Counsel & Corporate Secretary), Jing Marantz (Chief Medical Officer), Edward Myles (CFO), Caryn Parlavecchio (Insider), Katie Peng (Chief Commercial Officer, Denali Therapeutics), Mo Qatanani (Insider), and Tracey Sacco (Chief Commercial Officer). Learn More on Scholar Rock's active insiders.
Are insiders buying or selling shares of Scholar Rock?: In the last year, insiders at the sold shares 20 times. They sold a total of 2,141,013 shares worth more than $67,818,845.02. The most recent insider tranaction occured on March, 24th when insider Tracey Sacco sold 6,500 shares worth more than $215,020.00. Insiders at Scholar Rock own 19.2% of the company. Learn More about insider trades at Scholar Rock.
Information on this page was last updated on 3/24/2025.

Srinivas Akkaraju Insider Trading History at Scholar Rock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/7/2024	Sell	1,175,713	$29.25	$34,389,605.25	5,612,896

Srinivas Akkaraju Buying and Selling Activity at Scholar Rock

Scholar Rock Company Overview

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $32.84

$32.03

$33.96

50 Day Range

MA: $37.74

$32.16

$46.73

2 Week Range

Now: $32.84

$6.76

$46.98

Volume

1,129,184 shs

Average Volume

1,171,222 shs

Market Capitalization

$3.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59